Spectral MD Holdings Ltd. has received a $4 million award from the Medical Technology Enterprise Consortium (MTEC) to help develop a battlefield burn evaluation tool, the DeepView SnapShot M.

The funding will build upon work initially performed under a $1.1 million award from the U.S. Department of Defense and will support continued development of a fully portable device. The handheld DeepView SnapShot M would enable battlefield wounds to be triaged quickly and accurately so those with more severe burn injuries can be prioritized for potential evacuation. Development of the handheld device closely aligns with MTEC’s mission of facilitating prototype advancement of technologies that protect, treat, and optimize the health and performance of U.S. military service personnel.
 
“The unpredictability of severe burn injuries designates this wound type as a complex critical care problem in both military and civilian populations. Military conflict zones are often in remote locations, meaning that an accurate and immediate burn assessment is paramount for effective treatment and appropriate intervention,” MTEC Chief Scientific Officer Dr. Lauren Palestrini, Ph.D., said. “Developing the DeepView SnapShot M for remote applications enables medical providers to accurately inform triage, evacuation, and resourcing decisions, contributing to reduced surgical burden, and soldier return-to-duty.”
 
“We are honored to receive this award to support the military with the continued development of our DeepView technology, taking overall non-dilutive government funding commitments received to nearly $130 million,” Spectral MD CEO Wensheng Fan stated. “This funding will further Spectral MD’s innovation within the burn indication and support the continued development of our handheld digital burn assessment tool. We look forward to partnering with MTEC to advance our AI-driven diagnostic technology as we work toward FDA submission for the burn indication. Ultimately, we anticipate that our DeepView SnapShot M will transform wound care in many limited-access areas, including first responder, disaster preparedness and acute care emergency settings.”
 
Spectral MD is a predictive AI company focused on medical diagnostics for faster and more accurate treatment decisions in wound care for burn, DFU, and future clinical applications. The company aims to improve wound care management by “Seeing the Unknown” with its DeepView Wound Diagnostics System. Spectral MD’s DeepView platform is the only predictive diagnostic device that offers clinicians an objective and immediate assessment of a wound’s healing potential prior to treatment or other medical intervention. With algorithm-driven results that substantially exceed the current standard of care, Spectral MD’s diagnostic platform is expected to provide faster and more accurate treatment insight, significantly improving patient care and clinical outcomes. 
 
As announced on April 11, 2023, Spectral MD Holdings has agreed to combine with Rosecliff Acquisition Corp I, a special purpose acquisition company.
 
The U.S. Army Medical Research and Development Command is the Army’s medical materiel developer, with responsibility for medical research, development, and acquisition. USAMRDC produces medical solutions for the battlefield with a focus on various areas of biomedical research, including military infectious diseases, combat casualty care, military operational medicine, medical, chemical, and biological defense.
 
The MTEC is a 501(c)(3) biomedical technology consortium that is internationally dispersed, collaborating with multiple government agencies under a 10-year renewable Other Transaction Agreement with the U.S. Army Medical Research and Development Command. The consortium focuses on the development of medical solutions that protect, treat, and optimize the health and performance of U.S. service members and civilians. 

The U.S. Army Medical Materiel Development Activity is a subordinate command of the U.S. Army Medical Research and Development Command, under the Army Futures Command. As the developer of military medical capabilities, USAMMDA is responsible for developing and delivering critical products designed to protect and preserve the lives of warfighters. These products include drugs, vaccines, biologics, devices, and medical support equipment intended to maximize survival of casualties on the battlefield.